|
Huang, Xianming; Bennett, Mary; Thorpe, Philip E (2004) Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61:1-11
|
|
Mason, Ralph P; Constantinescu, Anca; Ran, Sophia et al. (2003) Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction. Adv Exp Med Biol 530:197-204
|
|
Ran, Sophia; Huang, Xianming; Downes, Amber et al. (2003) Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 5:297-307
|
|
Ran, Sophia; Downes, Amber; Thorpe, Philip E (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62:6132-40
|
|
Zhang, Wei; Ran, Sophia; Sambade, M et al. (2002) A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5:35-44
|
|
Mason, Ralph P; Ran, Sophia; Thorpe, Philip E (2002) Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. J Cell Biochem Suppl 39:45-53
|
|
Brekken, R A; Thorpe, P E (2001) Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 21:4221-9
|
|
Giatromanolaki, A; Sivridis, E; Athanassou, N et al. (2001) The angiogenic pathway ""vascular endothelial growth factor/flk-1(KDR)-receptor"" in rheumatoid arthritis and osteoarthritis. J Pathol 194:101-8
|
|
Gottstein, C; Wels, W; Ober, B et al. (2001) Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. Biotechniques 30:190-4, 196, 198 passim
|
|
Koukourakis, M I; Giatromanolaki, A; Thorpe, P E et al. (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088-95
|
Showing the most recent 10 out of 17 publications
